

Clinical Impact of Renin-angiotensin System Inhibitors on In-hospital Mortality of Patients With Hypertension Hospitalized for Coronavirus Disease 2019

TO THE EDITOR—We read with interest the article from Haffn et al, indicating key clinical research priorities to clarify the role of renin-angiotensin system (RAS) inhibition in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated coronavirus disease 2019 (COVID-19) [1].

Initial epidemiological studies have associated the presence of hypertension with a more severe disease and higher mortality rates [2, 3]. Nevertheless, it is unclear if this association is related to the pathogenesis of hypertension or to

advanced age, coexisting comorbidities, or antihypertensive treatment [4]. SARS-CoV-2 enters host cells after binding with angiotensin-converting enzyme 2 (ACE2); an overexpression of this enzyme has been described in hypertension, diabetes, and cardiovascular diseases, and in animal models of pharmacologic RAS blockade [1, 5]. Although the significance of ACE2 expression on COVID-19 pathogenesis and mortality is not specifically known, it has been hypothesized that overexpression may increase the risk of severe and fatal COVID-19 but also that RAS inhibition may mitigate clinical course, by interfering with the negative effects of angiotensin II on ACE2 downregulation in infected patients. Consequently, it has been proposed that either the use or avoidance/withdrawal of RAS inhibitors (RASIs) could

have a favorable impact on COVID-19 outcomes [1].

To date, clinical data about the role of RASIs in COVID-19 are lacking but are urgently needed, especially in Italy where the outbreak of COVID-19 is particularly heavy among elderly people [6], many of whom are prescribed RASIs to treat hypertension.

To investigate whether chronic treatment with RASIs has an impact on in-hospital mortality, we selected patients with hypertension from a cohort of prospectively enrolled adults with a microbiologically confirmed diagnosis of COVID-19, hospitalized in 10 Italian hospitals from 22 February to 4 April 2020.

The study population consisted of 311 patients with hypertension. They were significantly older; had a higher body

Table 1. Characteristics of the Study Population

Characteristic	All patients (N = 609)	Hypertension (n = 311)	No Hypertension (n = 298)	P Value
Age, y, median (IQR)	68 (55–80)	76 (67–83)	57 (47–68)	<.001
Male sex	410 (68)	225 (72)	185 (63)	.007
BMI, kg/m ² , median (IQR)	25 (23–28)	27 (24–31)	25 (23–27)	<.001
History of smoking	106 (17)	80 (26)	26 (9)	<.001
Influenza vaccination ^a	85/283 (30)	53/127 (42)	32/156 (20)	.02
Charlson index, median (IQR)	3 (1–5)	5 (3–6)	1 (0–3)	<.001
Comorbidities				
Diabetes	100 (16)	74 (24)	26 (9)	<.001
CVD	165 (27)	131 (42)	34 (11)	<.001
COPD	68 (11)	49 (16)	19 (6)	<.001
Immunosuppression	22 (4)	13 (4)	9 (3)	.44
Symptoms on admission				
Temperature ≥38°C	264 (46)	133 (46)	131 (45.5)	.60
Cough	349 (57)	157 (50)	192 (64)	.001
Dyspnea	253 (41)	138 (44)	115 (39)	.14
SOFA score, median (IQR)	2 (1–3)	2 (1–4)	1 (1–2)	<.001
Antihypertensive treatment ^b				
None	...	60 (19)	...	
ACEIs	...	99 (32)	...	
ARBs	...	76 (24.5)	...	
Others	...	76 (24.5)	...	
DNR	114 (19)	83 (27)	31 (10)	<.001
In-hospital mortality	179 (29)	131 (42)	43 (14)	<.001

Data are presented as no. (%) unless otherwise indicated.

Abbreviations: ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; DNR, do not resuscitate indication; IQR, interquartile range; SOFA, Sequential Organ Failure Assessment.

^aData about previous influenza vaccination were available for 283 of 609 patients.

^bData about antihypertensive medications were collected only for patients with a previous diagnosis of hypertension.

mass index; had a Charlson comorbidity index with a higher prevalence of cardiovascular (CV) comorbidities, chronic obstructive pulmonary disease (COPD), and diabetes; and had a higher Sequential Organ Failure Assessment (SOFA) score on admission compared with patients without hypertension (Table 1). Patients receiving antihypertensive drugs other than RASIs had a higher Charlson comorbidity index, with a higher prevalence of COPD and CV comorbidities.

Overall in-hospital mortality was 29% (179/609); among the 311 patients with hypertension, 131 (42%) died in-hospital, after a median of 6 days (interquartile range, 4–10 days) from admission.

In the group of patients with hypertension, in multivariate Cox regression analysis adjusted for age, sex, presence of CV comorbidities, and COPD, the independent predictors of in-hospital mortality were SOFA score on admission (adjusted hazard ratio [aHR], 1.32; 95% confidence interval [CI], 1.20–1.45; $P < .001$) and age (aHR, 1.05; 95% CI, 1.03–1.07; $P < .001$), whereas the chronic use of RASIs (aHR, 0.97; 95% CI, .68–1.39; $P = .88$) was not associated with outcome.

Our study population consists of aged patients with multiple comorbidities, from a hospital-based cohort with a probable selection bias for sicker cases, so in-hospital mortality is very high. Nevertheless, our findings support the statements of several scientific societies that recommend patients to continue

their current hypertensive medication regimen, waiting for the results of randomized controlled trials addressing the impact of RASIs on COVID-19 morbidity and mortality.

Notes

Acknowledgments. The authors acknowledge all of the members of the PREDI-CO study group who have contributed to data acquisition: Matteo Rinaldi, Linda Bussini, Giacomo Fornaro, Renato Pascale, Livia Pancaldi, Lorenzo Badia, Caterina Campoli, Luciano Attard, Luigi Raumer, Luca Guerra, Fabio Tumietto, Gabriella Verucchi, Eleonora Zamparini, Alessandra Cascavilla, Simona Coladonato, Francesca Volpato, Giulio Virgili, Nicolò Rossi, Elena Rosselli del Turco, Viola Guardigni, Eugenia Francalanci, Giovanni Fasulo, Nicola Dentale, Ciro Fulgaro, Giorgio Legnani, Tommaso Tonetti, V. Marco Ranieri, Giacinto Pizzilli, Elisabetta Pierucci, Paolo Gaibani, Giada Rossini, Caterina Vocale, Emanuele Campaci, Cristina Basso, Alberto Zuppiroli, Amalia Sanna Passino, Giulia Tesini, Lucia Angelelli, Adriana Badeanu, Agostino Rossi, Giulia Santangelo, Flovia Dauti, Vidak Koprivika, Nicholas Roncagli, Ioannis Tzimas, Guido Maria Liuzzi, Irid Baxhaku, Letizia Pasinelli, Mattia Neri, Tommaso Zanaboni, Francesco Dell'Omo, Oana Vatamanu, Alice Gori, Idina Zavatta, Stefano Antonini, Chiara Pironi, Elena Piccini, Luca Esposito, Alessandro Zuccotti, Giacomo Urbinati, Agnese Pratelli, Alberto Sarti, Michela Semprini, Enrico Evangelisti, Mara D'Onofrio, Giuseppe Sasdelli, Luigia Scudeller, Zeno Pasquini, Francesco Barchiesi, Massimo Puoti, Marco Merli, Cristina Mussini, Marianna Menozzi, Marianna Meschiari, Giovanni Guaraldi, Mauro Codeluppi, Maria Cristina Leoni, Elisa Fronti, Francesco Cristini, Lorenzo Marconi, Annalisa Saracino, Davide Bavaro, Paola Laghetti, Lucia Diella, Alberto Licci.

Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

Sara Tedeschi,¹ Maddalena Giannella,¹ Michele Bartoletti,¹ Filippo Trapani,¹ Marina Tadolini,¹ Claudio Borghi,² and Pierluigi Viale¹

¹Infectious Diseases Unit, Department of Medical and Surgical Sciences, Policlinico di Sant'Orsola, Bologna, Italy, and ²Internal Medicine, Department of Medical and Surgical Sciences, Policlinico di Sant'Orsola, Bologna, Italy

References

1. Hanff TC, Harhay MO, Brown TS, Cohen JB, Mohareb AM. Is there an association between COVID-19 mortality and the renin-angiotensin system—a call for epidemiologic investigations [manuscript published online ahead of print 26 March 2020]. Clin Infect Dis 2020. doi:10.1093/cid/ciaa329.
2. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China [manuscript published online ahead of print 13 March 2020]. JAMA Intern Med 2020. doi:10.1001/jamainternmed.2020.0994.
3. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395:1054–62.
4. Patel AB, Verma A. COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence? [manuscript published online ahead of print 24 March 2020]. JAMA 2020. doi:10.1001/jama.2020.4812.
5. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19. N Engl J Med 2020; 382:1653–9.
6. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy [manuscript published online ahead of print 23 March 2020]. JAMA 2020. doi:10.1001/jama.2020.4683.

Correspondence: S. Tedeschi, Infectious Diseases Unit, Policlinico di Sant'Orsola, Via Massarenti 11, Bologna 40138, Italy (sara.tedeschi@aosp.bo.it).

Clinical Infectious Diseases® 2020

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. DOI: 10.1093/cid/ciaa492